SEC Form 4	
------------	--

 \square

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or Section So(n) of the investment Company Act of 1940			
1. Name and Addres <u>Kennedy Giu</u>	ss of Reporting Perso <u>lia C</u>	n*	2. Issuer Name and Ticker or Trading Symbol VERACYTE, INC. [VCYT]		tionship of Reporting Perso all applicable) Director	on(s) to Issuer 10% Owner
(Last) 6000 SHORELI SUITE 300	(First) (Middle) ORELINE COURT 00		3. Date of Earliest Transaction (Month/Day/Year) 09/07/2021	X	Officer (give title below) Chief Scientific & M	Other (specify below)
(Street) SOUTH SAN FRANCISCO (City)	CA (State)	94080 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Filing Form filed by One Repor Form filed by More than Person	rting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

			• • • •									
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(1150.4)		
Common Stock	09/07/2021		M ⁽¹⁾		4,406	A	\$5.98	55,381	D			
Common Stock	09/07/2021		M ⁽¹⁾		3,750	A	\$20.21	59,131	D			
Common Stock	09/07/2021		M ⁽¹⁾		4,375	A	\$24.69	63,506	D			
Common Stock	09/07/2021		S ⁽¹⁾		12,034	D	\$50.519 ⁽²⁾	51,472	D			
Common Stock	09/07/2021		S ⁽¹⁾		497	D	\$51.233 ⁽³⁾	50,975	D			
Common Stock	09/08/2021		S ⁽¹⁾		926	D	\$50.53	50,049	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

			(0 /	• •		'		, I	,		,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expiration Date (Month/Day/Year)		ate Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.98	09/07/2021		M ⁽¹⁾			4,406	(4)	03/01/2028	Common Stock	4,406	\$0	8,813	D	
Stock Option (right to buy)	\$20.21	09/07/2021		M ⁽¹⁾			3,750	(5)	02/27/2029	Common Stock	3,750	\$0	22,500	D	
Stock Option (right to buy)	\$24.69	09/07/2021		M ⁽¹⁾			4,375	(6)	03/27/2030	Common Stock	4,375	\$0	43,750	D	

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

2. Represents weighted average sales price. Sale prices for the transactions range from \$50.06 to \$51.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from \$51.07 to \$51.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

4. The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

5. The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

6. The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

Remarks:

/s/ Jane Alley as attorney-in-

fact

09/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.